latest news releases from the newsroom
Ceragenix(TM) Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
DENVER, Jul 2, 2007 -- Ceragenix Pharmaceuticals, Inc. (CGXP), a biopharmaceutical company focused on infectious disease and dermatology, today announced that researchers at the University of Pennsylvania led by Dr. Paul Janmey and Dr. Robert Bucki, in collaboration with Dr. Paul B. Savage of Brigham Young University, have demonstrated in a series of in vitro experiments that an investigational drug compound known as CSA-13 shows promise as a potential therapy to treat multidrug resistant Pseudomonas aeuroginosa infections which are a leading cause of morbidity and mortality in patients with cystic fibrosis. The research appears ahead of print in an advanced online publication of the Journal of Antimicrobial Chemotherapy, the official journal of the British Society for Antimicrobial Chemotherapy.
Meade Instruments Corporation
Meade Instruments to Announce First Quarter 2008 Results On July 10, 2007
IRVINE, Calif., July 2, 2007 (PRIME NEWSWIRE) -- Meade Instruments Corp. (Nasdaq:MEAD) today announced that it will report financial results for its first quarter 2008 ending May 31, 2007 after market close on Tuesday, July 10, 2007. Following the press release, management will conduct a conference call with simultaneous web cast at 5:00 p.m. Eastern Time/ 2:00 p.m. Pacific Time to discuss the first quarter 2008 results and answer questions.